tbuckley/cabot-search huggingface dataset:
Abstract 38: Engineered Anisotropic Scaffolds Promote the Function of Cocultured Cardiomyocytes Derived From Human Pluripotent Stem Cells
Authors: Maureen Wanjare, Joseph Jung-Woong Kim, Ngan Huang
Journal: Circulation Research (2016)

Since the heart is effectively an anisotropic organ in which the cardiomyocytes (CM) are locally aligned in series, it is important to engineer cardiac tissues that promote CM alignment in order to closely mimic the architecture of the native tissue, as well as better mimic the cellular composition of the heart. The objective of this study was to define the role of anisotropic extracellular matrix cues on the organization and survival of human induced pluripotent stem cell-derived CMs (hiPSC-CMs) by co-culturing hiPSC-CMs and primary endothelial cells (ECs) on parallel-aligned microfibrillar scaffolds. The hiPSC-CMs were generated from hiPSCs using small molecule Wnt pathway agonists and antagonists. Subsequently, the hiPSC-CMs were sequentially seeded on day 15 after EC attachment. We cultured monocultures and cocultures on electrospun three-dimensional (3D) scaffolds of polycaprolactone (PCL) and polyethylene oxide (PEO) polymer blends with an average fiber diameter of 14 μm. Aligned scaffolds were fabricated by stretching the randomly oriented scaffolds by 300% of the original scaffold length. Randomly oriented fibrillar scaffolds had an average pore diameter of 17 μm when compared to the 36 μm pore diameter of aligned scaffolds. Our results indicate that alignment of co-cultured cells at a 5:1 hiPSC-CMs : EC ratio was promoted by anistropic 3D electrospun scaffolds when compared to similar random 3D electrospun scaffolds. Additionally, cocultured cells on aligned fibrillar scaffolds had a mean angle of orientation of 30.8°, relative to the direction of fibrils, which was similar to that of hiPSC-CM monocultures on aligned scaffolds (32.8°). In contrast, the degree of alignment of hiPSC-CMs on randomly oriented fibrillary scaffolds was 43.4°, which suggests a non-oriented population of cells. Aligned scaffolds also produced more synchronized cardiomyocyte contraction than random scaffold orientations, although both induced spontaneous contraction frequency of ~1Hz. This study highlights the importance of nanotopographical cues and intercellular interactions in mediating the morphology and contractility of hiPSC-CMs for treatment of cardiovascular diseases such as myocardial infarction.
Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke
Authors: Keun-Sik Hong, Sun U. Kwon, Sang Hun Lee, Ji Sung Lee, Yong-Jae Kim, Tae-Jin Song, Young Dae Kim, Man-Seok Park, Eung-Gyu Kim, Jae-Kwan Cha, Sang Min Sung, Byung-Woo Yoon, Oh Young Bang, Woo-Keun Seo, Yang-Ha Hwang, Seong Hwan Ahn, Dong-Wha Kang, Hyun Goo Kang, Kyung-Ho Yu
Journal: JAMA Neurology (2017)

<h3>Importance</h3> In atrial fibrillation (AF)–related acute ischemic stroke, the optimal oral anticoagulation strategy remains unclear. <h3>Objective</h3> To test whether rivaroxaban or warfarin sodium is safer and more effective for preventing early recurrent stroke in patients with AF-related acute ischemic stroke. <h3>Design, Setting, and Participants</h3> A randomized, multicenter, open-label, blinded end point evaluation, comparative phase 2 trial was conducted from April 28, 2014, to December 7, 2015, at 14 academic medical centers in South Korea among patients with mild AF-related stroke within the previous 5 days who were deemed suitable for early anticoagulation. Analysis was performed on a modified intent-to-treat basis. <h3>Interventions</h3> Participants were randomized 1:1 to receive rivaroxaban, 10 mg/d for 5 days followed by 15 or 20 mg/d, or warfarin with a target international normalized ratio of 2.0-3.0, for 4 weeks. <h3>Main Outcomes and Measures</h3> The primary end point was the composite of new ischemic lesion or new intracranial hemorrhage seen on results of magnetic resonance imaging at 4 weeks. Primary analysis was performed in patients who received at least 1 dose of study medications and completed follow-up magnetic resonance imaging. Key secondary end points were individual components of the primary end point and hospitalization length. <h3>Results</h3> Of 195 patients randomized, 183 individuals (76 women and 107 men; mean [SD] age, 70.4 [10.4] years) completed magnetic resonance imaging follow-up and were included in the primary end point analysis. The rivaroxaban group (n = 95) and warfarin group (n = 88) showed no differences in the primary end point (47 [49.5%] vs 48 [54.5%]; relative risk, 0.91; 95% CI, 0.69-1.20;<i>P</i> = .49) or its individual components (new ischemic lesion: 28 [29.5%] vs 31 of 87 [35.6%]; relative risk, 0.83; 95% CI, 0.54-1.26;<i>P</i> = .38; new intracranial hemorrhage: 30 [31.6%] vs 25 of 87 [28.7%]; relative risk, 1.10; 95% CI, 0.70-1.71;<i>P</i> = .68). Each group had 1 clinical ischemic stroke, and all new intracranial hemorrhages were asymptomatic hemorrhagic transformations. Hospitalization length was reduced with rivaroxaban compared with warfarin (median, 4.0 days [interquartile range, 2.0-6.0 days] vs 6.0 days [interquartile range, 4.0-8.0];<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> In mild AF-related acute ischemic stroke, rivaroxaban and warfarin had comparable safety and efficacy. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT02042534
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Authors: Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg
Journal: The Lancet (2017)
Very early molecular marker of tumor response to PD-1 inhibition in plasma of patients with advanced non-small cell lung cancer (NSCLC).
Authors: Thijo Jeroen Nicolaas Hiltermann, A Miedema, Lucie Hijmering-Kappelle, Harry J.M. Groen, Ed Schuuring
Journal: Journal of Clinical Oncology (2017)

3030 Background: Nivolumab shows a durable tumor response in 20 % of advanced NSCLC patients. While a PD-L1 immunohistochemistry complementary diagnostic has been approved, there is a need to identify a predictive biomarker with greater diagnostic accuracy. Methods: In an ongoing study of patients, treated with nivolumab every 2 weeks for advanced recurrent NSCLC and a known KRAS mutation in the primary tumor, liquid biopsies were taken by a simple blood draw at baseline (before treatment), 1, 2, 4, 6 and thereafter every 12 weeks until disease progression. Circulating tumor DNA (ctDNA) was extracted from cell free plasma and tested with a specific digital droplet PCR (ddPCR)-KRAS G12/G13 screenings assay (BIORAD). Mutation levels in plasma were compared with tumor response on CT scans by RECIST v.1.1. CT scans were performed at baseline and thereafter every 6 weeks until disease progression. Results: Patient characteristics are shown in table 1. In this prospective analysis specific patterns could be demonstrated in plasma ctDNA testing of KRAS mutation levels. All 4 responders showed an increase of mutant copies/ml plasma in the first week followed by a clear drop to non-detectable KRAS mutations at all CT evaluated tumor responses. The 2 non-responders however, did not show the increase in mutant copies/ml at one week and showed a gradual increase in mutant copies/ml in the following weeks. Conclusions: Specific plasma ctDNA testing seems a very promising early biomarker (1 week) for tumor response to PD-1 therapy. [Table: see text]
A Double-Blind, Randomized, Placebo-Controlled Trial of<i>Panax Ginseng</i>for Cancer-Related Fatigue in Patients With Advanced Cancer
Authors: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, Zhanni Lu, Kenneth R. Hess, Susan Frisbee-Hume, Helen L. House, Zita Dubauskas Lim, Kyu-Hyoung Lim, Gabriel Lopez, Akhila Reddy, Ahsan Azhar, Angelique Wong, Sunil M. Patel, Deborah A. Kuban, Ahmed Omar Kaseb, Lorenzo Cohen, Eduardo Bruera
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: Despite the high frequency, severity, and effects of cancer-related fatigue (CRF) on the quality of life (QoL) of patients with cancer, limited treatment options are available. The primary objective of this study was to compare the effects of oral Panax ginseng extract (PG) and placebo on CRF. Secondary objectives were to determine the effects of PG on QoL, mood, and function. Methods: In this randomized, double-blind, placebo-controlled study, patients with CRF ≥4/10 on the Edmonton Symptom Assessment System (ESAS) were eligible. Based on a pilot study, we randomized patients to receive either 400 mg of standardized PG twice daily or a matching placebo for 28 days. The primary end point was change in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale from baseline to day 29. Results: Of 127 patients, 112 (88.2%) were evaluable. The mean (SD) FACIT-F subscale scores at baseline, day 15, and day 29 were 22.4 (10.1), 29.9 (10.6), and 30.1 (11.6) for PG (P<.001), and 24.0 (9.4), 30.0 (10.1), and 30.4 (11.5) for placebo (P<.001). Mean (SD) improvement in the FACIT-F subscale at day 29 was not significantly different in the PG than in the placebo group (7.5 [12.7] vs 6.5 [9.9]; P=.67). QoL, anxiety, depression, symptoms, and functional scores were not significantly different between the PG and placebo groups. Improvement in the FACIT-F subscale correlated with baseline scores (P=.0005), Hospital Anxiety and Depression Scale results (P=.032), and sex (P=.023). There were fewer any-grade toxicities in the PG versus placebo group (28/63 vs 33/64; P=.024). Conclusions: Both PG and placebo result in significant improvement in CRF. PG was not significantly superior to placebo after 4 weeks of treatment. There is no justification to recommend the use of PG for CRF. Further studies are needed. Trial Registration: ClinicalTrials.gov identifier: NCT01375114.
薬剤耐性肺癌を阻害する有効miR 200c in vivo送達のための両親媒性ポリホスファゼンにより自己組織化した電気的中性複合ポリマーソーム【Powered by NICT】
Authors: Peng Yan, Zhu Xiumei, Qiu Liyan
Journal: Biomaterials (2016)
グラフェン結合による神経幹細胞の生体機能的開発の加速:導電性材料を用いた神経インタフェイスのための意味【Powered by NICT】
Authors: Guo Rongrong, Zhang Shasha, Xiao Miao, Qian Fuping, He Zuhong, Li Dan, Zhang Xiaoli, Li Huawei, Yang Xiaowei, Wang Ming, Chai Renjie, Tang Mingliang
Journal: Biomaterials (2016)
心不全の既往歴のない患者における将来起こりうる心不全に対する足関節上腕血圧指数の予後的重要性;IMPACT‐ABI登録のサブ解析
Authors: Nishimura Hitoshi, Miura Takashi, Shimizu Kunihiko, Shoin Wataru, Harada Mikiko, Mochidome Tomoaki, Ueki Yasushi, Yoshie Koji, Minamisawa Masatoshi, Hioki Hirofumi, Oguchi Yasutaka, Hashizume Naoto, Abe Naoyuki, Ebisawa Souichiro, Motoki Hirohiko, Okada Ayako, Shiba Yuji, Izawa Atsushi, Koyama Jun, Ikeda Uichi
Journal: Circulation (2016)
The diabetic heart utilizes ketone bodies as an energy source
Authors: Yuji Mizuno, Eisaku Harada, Hitoshi Nakagawa, Yoshinobu Morikawa, Makoto Shono, Fumihito Kugimiya, Michihiro Yoshimura, Hirofumi Yasue
Journal: Metabolism (2017)

Diabetic heart is characterized by failure of insulin to increase glucose uptake and increasingly relies on free fatty acids (FFAs) as a source of fuel in animal models. However, it is not well known how cardiac energy metabolism is altered in diabetic hearts in humans. We examined cardiac fuel metabolism in the diabetics as compared to non-diabetics who underwent cardiac catheterization for heart diseases.The study subjects comprised 81 patients (male 55, female 26, average age 63.0±10.0years) who underwent the cardiac catheterization for heart diseases. Thirty-six patients were diagnosed as diabetics (diabetic group) and 45 as non-diabetics (non-diabetic group). Blood samplings were done in both the aortic root (Ao) and coronary sinus (CS) simultaneously and the plasma levels of FFAs, glucose, lactate, pyruvate, total ketone bodies and β-hydroxybutyrate were measured and compared between the two groups.The myocardial uptake of glucose, lactate and pyruvate were decreased, whereas those of total ketone bodies, β-hydroxybutyrate and acetoacetate were increased in the diabetics as compared to the non-diabetics. However, the myocardial uptakes of FFAs were not significantly increased in the diabetics as compared to the non-diabetics.Cardiac uptakes of carbohydrate (glucose, lactate and pyruvate) were decreased, whereas those of total ketone bodies and β-hydroxybutyrate were increased in the diabetics as compared to the non-diabetics in humans. Ketone bodies therefore are utilized as an energy source partially replacing glucose in the human diabetic heart.
Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children
Authors: Franz Schaefer, Howard Trachtman, Elke Wühl, Marietta Kirchner, Salim S. Hayek, Ali Anarat, Ali Duzova, Sevgi Mir, Dusan Paripovic, Alev Yilmaz, Francesca Lugani, Klaus Arbeiter, Mieczyslaw Litwin, Jun Oh, Maria Chiara Matteucci, Jutta Gellermann, Simone Wygoda, Augustina Jankauskiene, Günter Klaus, Jiri Dusek, Sara Testa, Aleksandra Zurowska, Alberto Caldas Afonso, Melissa Tracy, Changli Wei, Sanja Sever, William Smoyer, Jochen Reiser
Journal: JAMA Pediatrics (2017)

Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss. Serum soluble urokinase receptor (suPAR) levels strongly predict incident CKD stage 3 in adults.
Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer
Authors: Allen S. Ho, Sungjin Kim, Mourad Tighiouart, Cynthia Gudino, Alain Mita, Kevin S. Scher, Anna Laury, Ravi Prasad, Stephen L. Shiao, Jennifer E. Van Eyk, Zachary S. Zumsteg
Journal: Journal of Clinical Oncology (2017)

Purpose Current staging systems for oral cavity cancers incorporate lymph node (LN) size and laterality, but place less weight on the total number of positive metastatic nodes. We investigated the independent impact of numerical metastatic LN burden on survival. Methods Adult patients with oral cavity squamous cell carcinoma undergoing upfront surgical resection for curative intent were identified in the National Cancer Data Base between 2004 and 2013. A neck dissection of a minimum of 10 LNs was required. Multivariable models were constructed to assess the association between the number of metastatic LNs and survival, adjusting for factors such as nodal size, laterality, extranodal extension, margin status, and adjuvant treatment. Results Overall, 14,554 patients met inclusion criteria (7,906 N0 patients; 6,648 node-positive patients). Mortality risk escalated continuously with increasing number of metastatic nodes without plateau, with the effect most pronounced with up to four LNs (HR, 1.34; 95% CI, 1.29 to 1.39; P < .001). Extranodal extension (HR, 1.41; 95% CI, 1.20 to 1.65; P < .001) and lower neck involvement (HR, 1.16; 95% CI, 1.06 to 1.27; P < .001) also predicted increased mortality. Increasing number of nodes examined was associated with improved survival, plateauing at 35 LNs (HR, 0.98; 95% CI, 0.98 to 0.99; P < .001). In multivariable models accounting for the number of metastatic nodes, contralateral LN involvement (N2c status) and LN size were not associated with mortality. A novel nodal staging system derived by recursive partitioning analysis exhibited greater concordance than the American Joint Committee on Cancer (8th edition) system. Conclusion The number of metastatic nodes is a critical predictor of oral cavity cancer mortality, eclipsing other features such as LN size and contralaterality in prognostic value. More robust incorporation of numerical metastatic LN burden may augment staging and better inform adjuvant treatment decisions.
Haploidentical transplants using partial T-cell depletion, cyclosporin and low-dose antithymocyte globulin as gvhd prophylaxis
Authors: James A. Russell, Ahsan M. Chaudhry, Peter Duggan, Douglas Stewart, Dean Ruether, Stefan Gluck, Don Morris, Max J. Coppes, Ron Anderson, Johannes Wolff, Maarten Egeler, Karen Booth, Sunil Desai, Loree Larratt, Robert Turner, Christopher B. Brown
Journal: Blood (2000)
HPV16 E6 oncoprotein modulates the DPPIV/CD26 in primary keratinocytes
Authors: Aline Beckenkamp, Bruna Prati, Silvya Stuchi Maria-Engler, Guido Lenz, Diogo André Pilger, Enrique Mario Boccardo Pierulivo, Andréia Buffon
Journal: Cancer Research (2017)
The role of a second endoscopic procedure after a failed first endoscopic mucosal resection for colorectal polyps
Authors: Fadi Antaki
Journal: Endoscopy (2017)

See also: Two-stage endoscopic mucosal resection is a safe and effective salvage therapy after a failed single-session approachEndoscopy 2017; 49(09): 888-898DOI: 10.1055/s-0043-110671
Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study
Authors: Jennifer G Jetton, Louis J Boohaker, Sidharth K Sethi, Sanjay Wazir, Smriti Rohatgi, Danielle E Soranno, Aftab S Chishti, Robert Woroniecki, Cherry Mammen, Jonathan R Swanson, Shanthy Sridhar, Craig S Wong, Juan C Kupferman, Russell L Griffin, David J Askenazi, David T Selewski, Subrata Sarkar, Alison Kent, Jeffery Fletcher, Carolyn L Abitbol, Marissa DeFreitas, Shahnaz Duara, Jennifer R Charlton, Ronnie Guillet, Carl D'Angio, Ayesa Mian, Erin Rademacher, Maroun J Mhanna, Rupesh Raina, Deepak Kumar, Namasivayam Ambalavanan, Ayse Akcan Arikan, Christopher J Rhee, Stuart L Goldstein, Amy T Nathan, Alok Bhutada, Shantanu Rastogi, Elizabeth Bonachea, Susan Ingraham, John Mahan, Arwa Nada, Patrick D Brophy, Tarah T Colaizy, Jonathan M Klein, F Sessions Cole, T Keefe Davis, Joshua Dower, Lawrence Milner, Alexandra Smith, Mamta Fuloria, Kimberly Reidy, Frederick J Kaskel, Jason Gien, Katja M Gist, Mina H Hanna, Sangeeta Hingorani, Michelle Starr, Catherine Joseph, Tara DuPont, Robin Ohls, Amy Staples, Surender Khokhar, Sofia Perazzo, Patricio E Ray, Mary Revenis, Anne Synnes, Pia Wintermark
Journal: The Lancet Child & Adolescent Health (2017)
アルカリ性環境におけるH_2O_2のための新しい近赤外蛍光プローブおよびin vitroおよびin vivo H_2O_2イメージングへの応用【Powered by NICT】
Authors: Liu Keyin, Shang Huiming, Kong Xiuqi, Ren Mingguang, Wang Jian-Yong, Liu Yong, Lin Weiying
Journal: Biomaterials (2016)
ヒト腫瘍と一次細胞におけるフェリチン媒介siRNA送達と遺伝子サイレンシング【Powered by NICT】
Authors: Li Le, Munoz-Culla Maider, Carmona Unai, Lopez Maria Paz, Yang Fan, Trigueros Cesar, Otaegui David, Zhang Lianbing, Knez Mato
Journal: Biomaterials (2016)
効果的な癌治療のためのドラッグデリバリー担体としての超細胞透過性ミセル【Powered by NICT】
Authors: Saw Phei Er, Yu Mikyung, Choi Minsuk, Lee Eunbeol, Jon Sangyong, C Farokhzad Omid
Journal: Biomaterials (2017)
Abstract 10890: Aortic Stiffness Predicts Clinical Outcome and Rate of Aortic Root Growth in Marfan Syndrome
Authors: Elif Seda Selamet Tierney, Jami C Levine, Lynn A Sleeper, Mary J Roman, Timothy J Bradley, Steven D Colan, Shan Chen, Michael Jay Campbell, Meryl S Cohen, Julie De Backer, Haleh Heydarian, Arvind Hoskoppal, Wyman W Lai, Aimee Liou, Edward Marcus, Arni Nutting, Aaron K Olson, Gail D Pearson, David Parra, Mary E Pierpont, Beth F Printz, Reed E Pyeritz, William Ravekes, Angela M Sharkey, Shubhika Srivastava, Luciana Young, Ronald V Lacro
Journal: Circulation (2015)

Background: The NHLBI Pediatric Heart Network randomized trial of atenolol vs. losartan in Marfan Syndrome demonstrated no significant treatment difference in the rate of change in body surface area adjusted maximum aortic root diameter z score (AoRz). Objectives: To report trial results on aortic stiffness and to determine whether aortic stiffness predicts clinical outcome and change in AoRz. Methods: 608 patients (6 mo - 25 yr) who met original Ghent criteria and had AoRz &gt; 3 were enrolled. Echocardiograms obtained at 0, 6, 12, 24 &amp; 36 months were centrally interpreted. Aortic dimensions were measured by 2D imaging, and stiffness indices were calculated for aortic root (AoR) and ascending aorta (AA). Where appropriate, stiffness measurements were indexed to 1/sqrt(R-R interval) to adjust for heart rate. Data were analyzed by multivariable mixed effects modeling and Cox regression. Results: The rate of change over three years in heart rate-adjusted AoR stiffness index differed by treatment (p = 0.016), with a decrease in the atenolol group and no significant change in the losartan group (-0.29 ± 0.14 vs. 0.14 ± 0.14/year). There was no significant treatment effect on the rate of change for AA stiffness index or for elastic modulus (AoR and AA). In the entire cohort, baseline AoR but not the AA stiffness index predicted the rate of change in ARz, with above-average stiffness index (≥ 10) predicting a slower annual decline of AoRz (-0.08 ± 0.02 vs. -0.15 ± 0.01 for below-average stiffness, p &lt; 0.001), even after adjusting for baseline age. Elastic modulus was not a significant predictor of rate of change in AoRz. AoR elastic modulus &gt;122 kPA (75th %ile) independently predicted the composite outcome of AoR surgery, dissection or death (hazard ratio 2.17, 95% CI 1.02 - 4.63, p = 0.04), controlling for baseline age and AoRz. Crude 3-year event rates were 10.4% vs. 3.2% for higher vs. lower elastic modulus groups, respectively. Conclusions: Atenolol reduced AoR stiffness over 3 years, while losartan did not. In this medically-treated cohort, higher baseline AoR stiffness was associated with a smaller decrease in AoRz, and a greater hazard of AoR dissection/surgery/death. These data suggest that aortic stiffness measures may identify patients at higher risk and guide management.
Relative Energy Deficiency in Sport (RED-S)
Journal: British Journal of Sports Medicine (2015)

What is the RED-S CAT?the ReD-S cat is a clinical assessment tool for the evaluation of athletes / active individuals suspected of having relative energy defi ciency and for guiding return to play decisions.the ReD-S cat is designed for use by a medical professional in the clinical evaluation and management of athletes with this syndrome.the ReD-S cat is based on the ioc consensus Statement on ReD-S, 2014. 1 this tool may be freely copied in its current form for use by sport organizations and the athlete medical team entourage.alterations to the tool or reproduction for publication purposes require permission from the international olympic committee.NOTE: the diagnosis of ReD-S is a medical diagnosis to be made by a trained health care professional.clinical management and return to play decisions for athletes with ReD-S should occur under the guidance of an experienced sports medicine team. What is Relative Energy Defi ciency in Sport?The syndrome of RED-S refers to impaired physiological functioning caused by relative energy defi ciency, and includes but is not limited to impairments of metabolic rate, menstrual function, bone health, immunity, protein synthesis, and cardiovascular health.
B型ナトリウム利尿ペプチドは慢性心不全患者の長期予後を予測する―CHART‐2研究からの報告―
Authors: Kasahara Shintaro, Sakata Yasuhiko, Miura Masanobu, Ushigome Ryoichi, Sato Kenjiro, Tadaki Soichiro, Onose Takeo, Tsuji Kanako, Yamauchi Takeshi, Abe Ruri, Oikawa Takuya, Takahashi Jun, Miyata Satoshi, Shimokawa Hiroaki
Journal: Circulation (2016)
Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Kristen Beyer, Anthony Proli, Junting Zheng, Sean Devlin, Valkal Bhatt, Andrew Lin, Esperanza B. Papadopoulos, Ann A. Jakubowski, Miguel Perales, Sergio Giralt, Hugo Castro-Malaspina, Roni Tamari
Journal: Blood (2016)